U.S. FDA leaning toward approving Moderna half-dose booster -Bloomberg News
Sept 28 (Reuters) – The U.S. Food and Drug Administration (FDA) is leaning toward authorizing half-dose booster shots of the Moderna Inc (MRNA.O) COVID-19 vaccine, Bloomberg News reported on Tuesday, citing people familiar with the matter.
The FDA had been seeking information about the effectiveness of a full third dose of the Moderna vaccine, but is now ready to move forward and consider the half-dose booster Moderna has proposed, the report said.
Moderna and the FDA did not immediately respond to Reuters request for comment outside regular business hours.
Moderna on Sept. 1 submitted its application to the U.S. Food and Drug Administration seeking authorization for a booster shot. The original Moderna vaccine contains 100-micrograms of mRNA in each shot. The company’s submission to regulators to authorize a half-dose booster would allow Moderna to produce more.
